The Research Support Services Core provides administrative and budget management support for each Project and Core so that research goals may be achieved. Specific services are as follows: 1. Administrative and secretarial a) Organize the monthly scientific meeting of PPG investigators, including WebEx arrangements b) Coordinate the annual meeting of PPG investigators with Ext. Advisory Committee, and concomitant meeting of all NANT site principal investigators in Los Angeles. c) Assist with the Clinical Trials Agreements for the 15 NANT Consortium institutions and any industry sponsored NANT clinical trials d) Assist Project and Core Leaders with the preparation of grants and annual progress report to NCI e) Act as a liaison between CHLA, USC, and UCSF to facilitate subcontract agreements f) Assist Dr. Seeger with annual review of each Project and Core taking into account the External Scientific Review Committee written report, peer reviewed publications, presentations at scientific meetings, generation of phase I clinical protocols g) Provide administrative support to NANT Data Safety Monitoring Board(DSMB), Scientific Review Committee, and Study Management Committees, and assist with development of NANT SOP's;these are key components of Project 4 clinical trials consortium h) Maintain and upgrade NANT website (www.nant.org) as needed;website provides critical information tool for NANT clinical trials consortium i) Insure that all regulatory and compliance requirements are met for animal experimentation and human investigations j) Provide miscellaneous administrative support for Project 1- 4 2. Budget management a) Manage budget for all Projects and Cores b) Manage disbursements of funds for subcontracts with external institutions (USC, UCSF) and for capitation and correlative specimens to NANT consortium institutions c) Reimbursements for participants in Annual PPG and NANT meeting d) Honoraria for NANT DSMB members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA081403-11
Application #
7897377
Study Section
Special Emphasis Panel (ZCA1-GRB-S (J1))
Project Start
2010-06-01
Project End
2015-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
11
Fiscal Year
2010
Total Cost
$37,364
Indirect Cost
Name
Children's Hospital of Los Angeles
Department
Type
DUNS #
052277936
City
Los Angeles
State
CA
Country
United States
Zip Code
90027
Pinto, Navin; DuBois, Steven G; Marachelian, Araz et al. (2018) Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer 65:e27023
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Villablanca, Judith G; Ji, Lingyun; Shapira-Lewinson, Adi et al. (2018) Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer 65:e26940
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Webb, Matthew W; Sun, Jianping; Sheard, Michael A et al. (2018) Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes. Int J Cancer 143:1483-1493
Tran, Hung C; Wan, Zesheng; Sheard, Michael A et al. (2017) TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. Clin Cancer Res 23:804-813
Cho, Hwang Eui; Min, H Kang (2017) Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. J Pharm Biomed Anal 132:117-124
Zheng, Tina; Ménard, Marie; Weiss, William A (2017) Neuroblastoma Metastases: Leveraging the Avian Neural Crest. Cancer Cell 32:395-397
Erdreich-Epstein, Anat; Singh, Alok R; Joshi, Shweta et al. (2017) Association of high microvessel ?v?3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget 8:52193-52210
Marachelian, Araz; Villablanca, Judith G; Liu, Cathy W et al. (2017) Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res 23:5374-5383

Showing the most recent 10 out of 150 publications